Listen

Press releases

Receive e-mail alerts

Interne link ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
april 14, 2025 om 11:00 AM UTC
Interne link ProQR Announces Year End 2024 Operating and Financial Results
maart 13, 2025 om 11:00 AM UTC
Interne link ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital
december 30, 2021 om 12:00 PM UTC
Interne link ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
december 16, 2021 om 12:00 PM UTC
Interne link ProQR Announces Highlights from Analyst Event
november 18, 2021 om 09:01 PM UTC
Interne link ProQR to Webcast Virtual Analyst Event on November 18
november 11, 2021 om 12:00 PM UTC
Interne link ProQR Announces Upcoming Investor Conferences in November and December
november 08, 2021 om 09:30 PM UTC
Interne link ProQR Announces Third Quarter 2021 Operating and Financial Results
november 04, 2021 om 11:00 AM UTC
Interne link ProQR Appoints Theresa Heggie as Chief Commercial Officer
oktober 04, 2021 om 12:00 PM UTC
Interne link ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform
september 08, 2021 om 08:15 PM UTC
Interne link ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
september 08, 2021 om 08:01 PM UTC
Interne link ProQR Announces Virtual Presentation at EURETINA 2021
september 06, 2021 om 08:15 PM UTC
Interne link ProQR Announces Upcoming Investor Conferences
september 03, 2021 om 12:00 PM UTC
Interne link ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Ophthalmology Virtual Conference
augustus 11, 2021 om 08:30 PM UTC
Interne link ProQR Announces Second Quarter 2021 Operating and Financial Results
augustus 05, 2021 om 11:00 AM UTC
Interne link ProQR to Present at Upcoming JMP Securities Life Sciences Conference
juni 10, 2021 om 11:00 AM UTC
Interne link ProQR Announces First Quarter 2021 Operating and Financial Results
mei 06, 2021 om 11:00 AM UTC
Interne link ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target
mei 04, 2021 om 11:00 AM UTC
Interne link ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021
april 23, 2021 om 11:00 AM UTC
Interne link ProQR Announces Participation in Upcoming Kempen Life Sciences Conference
april 22, 2021 om 11:00 AM UTC
Interne link ProQR Announces Annual Meeting of Shareholders
april 20, 2021 om 11:00 AM UTC
Interne link ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10
april 13, 2021 om 08:15 PM UTC
Interne link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
april 05, 2021 om 08:15 PM UTC
Interne link ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021
april 02, 2021 om 08:15 PM UTC
Interne link ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares
maart 31, 2021 om 02:25 AM UTC

Press releases

Interne link ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

Interne link ProQR Announces Year End 2024 Operating and Financial Results

Interne link ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital

Interne link ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa

Interne link ProQR Announces Highlights from Analyst Event

Interne link ProQR to Webcast Virtual Analyst Event on November 18

Interne link ProQR Announces Upcoming Investor Conferences in November and December

Interne link ProQR Announces Third Quarter 2021 Operating and Financial Results

Interne link ProQR Appoints Theresa Heggie as Chief Commercial Officer

Interne link ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform

Interne link ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly

Interne link ProQR Announces Virtual Presentation at EURETINA 2021

Interne link ProQR Announces Upcoming Investor Conferences

Interne link ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Ophthalmology Virtual Conference

Interne link ProQR Announces Second Quarter 2021 Operating and Financial Results

Interne link ProQR to Present at Upcoming JMP Securities Life Sciences Conference

Interne link ProQR Announces First Quarter 2021 Operating and Financial Results

Interne link ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target

Interne link ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021

Interne link ProQR Announces Participation in Upcoming Kempen Life Sciences Conference

Interne link ProQR Announces Annual Meeting of Shareholders

Interne link ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10

Interne link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

Interne link ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021

Interne link ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares